Alexia Iasonos, PhD

Attending Biostatistician
Epidemiology & Biostatistics
Directory
Epidemiology
Biostatistics
Health Outcomes
Computational Oncology
Administrative Resources
Career Opportunities
Educational Opportunities
Departmental Newsletter

Alexia Iasonos, PhD

Attending Biostatistician
Share
Share
Alexia Iasonos, Attending Biostatistician

Email

[email protected]

Education

University of Albany

Current Research Interests

Dr. Iasonos has been at MSKCC since 2005. She has collaborated primarily with investigators studying ovarian cancer and also with investigative teams studying bladder cancer, lymphoma, and health outcomes. Through her collaborations with investigators in gynecology (Departments of Surgery, Medicine and Pathology) she is exploring various biomarkers and assessing relationships to histology, metastasis and clinical outcome. She is also involved in vaccine trials as a second line therapy in ovarian cancer patients, and in identifying valid endpoints for these trials. Her methodological interests focus on model-based designs that guide the dose escalation in phase I trials and in the past few years she has focused on the design of early phase trials that involve dose expansion cohorts.

Publications

Selected peer-reviewed publications:

  1. Iasonos A, O’Quigley J. Dose expansion cohorts in Phase I trials. Stat Biopharm Res. 2016;8(2):161-170. Epub 2016 Jun 2. PubMed PMID: 27516848; PubMed Central PMCID: PMC4976787.
  2. Iasonos A, O’Quigley J. Clinical trials: Early phase clinical trials-are dose expansion cohorts needed? Nat Rev Clin Oncol. 2015 Nov;12(11):626-8. doi:10.1038/nrclinonc.2015.174. Epub 2015 Oct 6. PubMed PMID: 26441082; PubMed Central PMCID: PMC4758199.
  3. Satagopan JM, Iasonos A. Measuring differential treatment benefit across marker specific subgroups: The choice of outcome scale. Contemp Clin Trials. 2017 Feb 22. pii: S1551-7144(16)30093-3. doi: 10.1016/j.cct.2017.02.007. [Epub ahead of print] PubMed PMID: 28254404.
  4. Iasonos A, O’Quigley J. Adaptive dose-finding studies: a review of model-guided phase I clinical trials. J Clin Oncol. 2014 Aug 10;32(23):2505-11. doi: 10.1200/JCO.2013.54.6051. Epub 2014 Jun 30. Review. PubMed PMID: 24982451; PubMed Central PMCID: PMC4121508.
  5. Iasonos A, Schrag D, Raj GV, Panageas KS. How to build and interpret a nomogram for cancer prognosis. J Clin Oncol. 2008 Mar 10;26(8):1364-70. doi: 10.1200/JCO.2007.12.9791. Review.

Visit PubMed for a full listing of Alexia Iasonos’ journal articles

Pubmed is an online index of biomedical articles maintained by the U.S. National Library of Medicine and the National Institutes of Health.

My Downloads

My Pages

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Alexia Iasonos discloses the following relationships and financial interests:

  • Chapman and Hall
    Intellectual Property Rights
  • Intelligencia Inc.
    Professional Services and Activities
  • Journal of Clinical Oncology
    Professional Services and Activities
  • Mirati Therapeutics
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures